259 related articles for article (PubMed ID: 15273255)
1. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
Hirsh AJ; Sabater JR; Zamurs A; Smith RT; Paradiso AM; Hopkins S; Abraham WM; Boucher RC
J Pharmacol Exp Ther; 2004 Dec; 311(3):929-38. PubMed ID: 15273255
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.
Hirsh AJ; Zhang J; Zamurs A; Fleegle J; Thelin WR; Caldwell RA; Sabater JR; Abraham WM; Donowitz M; Cha B; Johnson KB; St George JA; Johnson MR; Boucher RC
J Pharmacol Exp Ther; 2008 Apr; 325(1):77-88. PubMed ID: 18218832
[TBL] [Abstract][Full Text] [Related]
3. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Mall MA
Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
[TBL] [Abstract][Full Text] [Related]
4. [Benzamil and mucoviscidosis. Primary culture of nasal mucosa as an electrophysiologic in vitro model].
Blank U; Glanz H; Eistert B; Fryen A; Lindemann H; Hüls G; Clauss W; Weber WM
HNO; 1996 Apr; 44(4):172-7. PubMed ID: 8655347
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
Hirsh AJ; Molino BF; Zhang J; Astakhova N; Geiss WB; Sargent BJ; Swenson BD; Usyatinsky A; Wyle MJ; Boucher RC; Smith RT; Zamurs A; Johnson MR
J Med Chem; 2006 Jul; 49(14):4098-115. PubMed ID: 16821771
[TBL] [Abstract][Full Text] [Related]
6. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice.
Zhou Z; Treis D; Schubert SC; Harm M; Schatterny J; Hirtz S; Duerr J; Boucher RC; Mall MA
Am J Respir Crit Care Med; 2008 Dec; 178(12):1245-56. PubMed ID: 18849497
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the epithelial Na+ channel ENaC outer pore disrupt amiloride block by increasing its dissociation rate.
Kellenberger S; Gautschi I; Schild L
Mol Pharmacol; 2003 Oct; 64(4):848-56. PubMed ID: 14500741
[TBL] [Abstract][Full Text] [Related]
8. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Zhang LN; Karp P; Gerard CJ; Pastor E; Laux D; Munson K; Yan Z; Liu X; Godwin S; Thomas CP; Zabner J; Shi H; Caldwell CW; Peluso R; Carter B; Engelhardt JF
Mol Ther; 2004 Dec; 10(6):990-1002. PubMed ID: 15564131
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.
Knowles MR; Church NL; Waltner WE; Yankaskas JR; Gilligan P; King M; Edwards LJ; Helms RW; Boucher RC
N Engl J Med; 1990 Apr; 322(17):1189-94. PubMed ID: 2157983
[TBL] [Abstract][Full Text] [Related]
10. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis.
Rodgers HC; Knox AJ
Eur Respir J; 1999 Sep; 14(3):693-6. PubMed ID: 10543294
[TBL] [Abstract][Full Text] [Related]
11. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.
App EM; King M; Helfesrieder R; Köhler D; Matthys H
Am Rev Respir Dis; 1990 Mar; 141(3):605-12. PubMed ID: 2310093
[TBL] [Abstract][Full Text] [Related]
12. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis.
Hofmann T; Stutts MJ; Ziersch A; Rückes C; Weber WM; Knowles MR; Lindemann H; Boucher RC
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1844-9. PubMed ID: 9620916
[TBL] [Abstract][Full Text] [Related]
13. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
Mall M; Grubb BR; Harkema JR; O'Neal WK; Boucher RC
Nat Med; 2004 May; 10(5):487-93. PubMed ID: 15077107
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine inhibits Na+ absorption across human nasal epithelial cells.
Rochat T; Lacroix JS; Jornot L
J Cell Physiol; 2004 Oct; 201(1):106-16. PubMed ID: 15281093
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mechanical activation of guinea-pig airway afferent neurons by amiloride analogues.
Carr MJ; Gover TD; Weinreich D; Undem BJ
Br J Pharmacol; 2001 Aug; 133(8):1255-62. PubMed ID: 11498511
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis and non-cystic-fibrosis human nasal epithelium show analogous Na+ absorption and reversible block by phenamil.
Blank U; Rückes C; Clauss W; Hofmann T; Lindemann H; Münker G; Weber W
Pflugers Arch; 1997 May; 434(1):19-24. PubMed ID: 9094252
[TBL] [Abstract][Full Text] [Related]
17. Benzamil, a blocker of epithelial Na(+) channel-induced upregulation of artery oxygen pressure level in acute lung injury rabbit ventilated with high frequency oscillation.
Taguchi N; Niisato N; Sawabe Y; Miyazaki H; Hirai Y; Marunaka Y
Biochem Biophys Res Commun; 2005 Feb; 327(3):915-9. PubMed ID: 15649432
[TBL] [Abstract][Full Text] [Related]
18. Epithelial Na+ channel and ion transport in human nasal polyp and paranasal sinus mucosa.
Yasuda M; Niisato N; Miyazaki H; Iwasaki Y; Hama T; Dejima K; Hisa Y; Marunaka Y
Biochem Biophys Res Commun; 2007 Oct; 362(3):753-8. PubMed ID: 17765200
[TBL] [Abstract][Full Text] [Related]
19. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells.
Noël S; Wilke M; Bot AG; De Jonge HR; Becq F
J Pharmacol Exp Ther; 2008 Jun; 325(3):1016-23. PubMed ID: 18309088
[TBL] [Abstract][Full Text] [Related]
20. ENaC- and CFTR-dependent ion and fluid transport in human middle ear epithelial cells.
Choi JY; Son EJ; Kim JL; Lee JH; Park HY; Kim SH; Song MH; Yoon JH
Hear Res; 2006 Jan; 211(1-2):26-32. PubMed ID: 16226002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
